Table 2.

Median specific gravity adjusted phthalate metabolite¹ and pCRH concentrations by study visit, gestational hypertension (GHTN; n=102), and gestational diabetes (GDM; n=59).

	VISIT 1 (16–29 weeks; n=1018)					VISIT 2 (22–39 weeks; n=1014)
	Total cohort	No GHTN	GHTN	No GDM	GDM	Total cohort	No GHTN	GHTN	No GDM	GDM
Phthalate metabolites (ng/mL)
MBP	29.80	29.66	32.13	29.87	26.22	16.06	15.67	18.29	16.04	13.55
MBzP	19.35	18.68	21.20	18.98	18.67	10.40	10.20	12.79	10.48	9.17
MCINP	3.06	3.12	2.85	3.06	3.89	0.48	0.47	0.59	0.48	0.38
MCIOP	11.84	12.21	11.44	11.84	12.81	2.21	2.16	2.59	2.22	2.01
MCPP	1.95	1.96	1.94	1.96	1.78	1.43	1.40	1.77	1.43	1.28
MCMHP	16.32	16.32	16.65	16.31	16.68	6.24	6.13	6.47	6.26	4.77
MECPP	17.21	16.89	19.69	17.28	17.96	11.90	11.65	13.37	11.90	9.19
MEHHP	26.18	26.12	27.33	26.22	26.40	8.27	8.12	9.60	8.38	5.99
MEHP	7.01	6.97	7.92	7.09	5.27	2.31	2.30	2.11	2.33	1.65
MEOHP	12.50	12.46	13.59	12.56	12.60	6.28	6.19	6.94	6.33	4.43
MEP	122.08	119.00	155.15	122.60	99.52	111.84	110.72	116.17	113.76	61.14
MHPP	1.10	1.12	1.01	1.10	1.12	0.37	0.36	0.41	0.37	0.36
MiBP	11.96	11.83	11.70	11.96	10.57	7.74	7.59	8.73	7.76	5.89
MMP	4.95	5.05	4.92	5.14	2.38	2.39	2.36	2.82	2.40	2.11
PA	59.53	58.53	72.75	59.46	65.27	70.12	68.06	81.06	70.41	58.86
pCRH (pg/mL)	37.60	37.97	40.28	37.81	41.81	235.20	229.90	334.88	230.96	313.85

¹LODs for phthalate metabolites range from 0.012 to 0.137.